Full Generic Medicine Info
Dosage/Direction for Use

Seasonal allergic rhinitis
Adult: As 0.6% spray: 2 sprays into each nostril bid.
Child: 6-11 year 1 spray into each nostril bid.

Allergic conjunctivitis
Adult: As 0.1% soln: 1 drop in the affected eye(s) bid at an interval of 6-8 hr. As 0.2% soln: 1 drop in the affected eye(s) once daily.
Child: ≥3 yr Same as adult dose.
Special Precautions
Not intended for contact lens-related irritation (ophth). Patient w/ other nasal disease. Pregnancy and lactation. Patient Counselling May impair ability to engage in activities requiring complete mental alertness and motor coordination (e.g. driving or operating machinery) after admin of the nasal spray. Ophth: Remove contact lenses prior to eye admin. Reinsert contact lenses 10 min after admin. Do not wear contact lenses if eyes are red. Improper handling may contaminate soln w/ bacteria that may cause ocular infections. Tip of the dispensing container should not be in contact w/ eye, eyelids or surrounding structures. Monitoring Parameters Nasal examinations should be performed periodically for signs of adverse effects on the nasal mucosa.
Adverse Reactions
Headache, somnolence. Symptoms similar to cold syndrome and pharyngitis, blurred vision, ocular burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid oedema, or ocular pain or pruritus. Nasal: Bitter taste, epistaxis, pyrexia, rash, nasal ulceration and septal perforation, pharyngolaryngeal pain, postnasal drip, cough, UTI, upper resp tract infection.
Symptoms: Drowsiness in adults and, initially, agitation and restlessness, followed by drowsiness in childn. Management: Symptomatic or supportive treatment.
Drug Interactions
May result in additive CNS depression w/ CNS depressants.
Food Interaction
Concomitant use w/ alcohol may result in additive CNS depression (nasal).
Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
Onset: 30 min (nasal).
Absorption: Ophth: Minimal. Bioavailability: 57% (nasal). Time to peak plasma concentration: 15 min to 2 hr (nasal).
Distribution: Plasma protein binding: Approx 55% (mainly albumin).
Metabolism: Not extensively metabolised.
Excretion: Via urine (60-70% as unchanged drug); faeces (approx 17%). Elimination half-life: 8-12 hr.
Nasal: Store below 25°C. Ophthalmic: Store below 25°C.
CIMS Class
Nasal Decongestants & Other Nasal Preparations / Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories
ATC Classification
R01AC08 - olopatadine ; Belongs to the class of topical antiallergic preparations, excluding corticosteroids. Used as antiallergic agents.
S01GX09 - olopatadine ; Belongs to the class of other ophthalmologic antiallergics.
Disclaimer: This information is independently developed by CIMS based on olopatadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in